| TITLE |
DATE |
| Rigel to Present at Oppenheimer Annual Healthcare Conference |
7-Dec-2011 |
| Rigel to Participate at Two Upcoming Investor Conferences |
3-Nov-2011 |
| Rigel Announces Third Quarter 2011 Financial Results |
1-Nov-2011 |
| Rigel to Webcast Investor Day on October 13, 2011 |
6-Oct-2011 |
| Rigel to Present at Two Upcoming Investor Conferences |
25-Aug-2011 |
| Rigel Announces Second Quarter 2011 Financial Results |
2-Aug-2011 |
| Rigel to Present at Wells Fargo Securities Healthcare Conference |
16-Jun-2011 |
| Rigel to Present at Jefferies Global Healthcare Conference |
3-Jun-2011 |
| Rigel Announces Pricing of Public Offering of Common Stock |
26-May-2011 |
| Rigel Announces Proposed Public Offering of Common Stock |
25-May-2011 |
| Rigel Assumes Development Responsibility for Inhaled Asthma Therapy |
6-May-2011 |
| Rigel to Present at Bank of America Merrill Lynch Health Care Conference |
5-May-2011 |
| Rigel Announces First Quarter Financial Results |
3-May-2011 |
| Rigel Announces Fourth Quarter and Year End 2010 Financial Results |
1-Mar-2011 |
| Rigel to Present at Three Upcoming Investor Conferences |
28-Feb-2011 |
| Rigel Announces Participation at Two Investor Conferences |
9-Feb-2011 |
| Rigel to Present at JP Morgan Healthcare Conference |
6-Jan-2011 |
| Rigel and AstraZeneca Awarded 'Licensing Deal of the Year' by Scrip for Fostamatinib Collaboration |
9-Dec-2010 |
| Rigel to Present at Piper Jaffray Health Care Conference |
23-Nov-2010 |
| Rigel Announces Third Quarter 2010 Financial Results |
2-Nov-2010 |
| Rigel Announces Presentations at Two Investor Conferences |
28-Oct-2010 |
| Rigel Earns Milestone Payments From AstraZeneca |
29-Sep-2010 |
| Data Published Today Reveal That Novel Oral Therapy Fostamatinib Demonstrates Positive Response in Rheumatoid Arthritis Patients |
22-Sep-2010 |
| Rigel to Present at Stifel Nicolaus Healthcare Conference |
9-Sep-2010 |
| Rigel Announces Second Quarter 2010 Financial Results |
3-Aug-2010 |
| Rigel to Present at BMO Capital Markets Healthcare Conference |
28-Jul-2010 |
| Rigel Announces Presentation at Three Investor Conferences |
3-Jun-2010 |
| Rigel Pharmaceuticals Names Raul Rodriguez President |
1-Jun-2010 |
| Rigel Announces First Quarter 2010 Financial Results |
4-May-2010 |
| Rigel Receives Innovators Award of Excellence in Life Sciences |
30-Apr-2010 |
| Rigel Announces Expiry of Waiting Period Under Hart-Scott-Rodino Act for Licensing Agreement With Astrazeneca |
29-Mar-2010 |
| Rigel to Webcast Investor Day on March 25, 2010 |
18-Mar-2010 |
| Rigel to Present at Barclays Capital Healthcare Conference |
17-Mar-2010 |
| Rigel to Present at Cowen and Company Health Care Conference |
5-Mar-2010 |
| Rigel Announces Fourth Quarter and Year End 2009 Financial Results |
2-Mar-2010 |
| Rigel to Host Conference Call Today to Discuss Its Partnership With AstraZeneca on Fostamatinib Disodium (R788) |
16-Feb-2010 |
| AstraZeneca and Rigel Pharmaceuticals Sign Worldwide License Agreement for Late-Stage Development Product -- Fostamatinib Disodium (R788) -- for the Treatment of Rheumatoid Arthritis (RA) |
16-Feb-2010 |
| Rigel to Present at BIO CEO & Investor Conference |
5-Feb-2010 |
| Rigel Receives Milestone Payment from Daiichi Sankyo for Cancer Ligase Target |
23-Dec-2009 |
| Eleven Rigel Product Candidate Presentations at 2009 ASH Meeting |
1-Dec-2009 |
| Rigel Announces Third Quarter 2009 Financial Results |
3-Nov-2009 |
| Rigel Announces Presentations at Two Investor Conferences |
28-Oct-2009 |
| Rigel to Webcast Analyst Briefing on October 20, 2009 |
16-Oct-2009 |
| Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock |
17-Sep-2009 |
| Rigel Announces Proposed Offering of 6,000,000 Shares of Common Stock |
16-Sep-2009 |
| Rigel Announces Second Quarter 2009 Financial Results |
4-Aug-2009 |
| R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent |
23-Jul-2009 |
| Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis |
23-Jul-2009 |
| Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial |
9-Jul-2009 |
| Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis |
8-Jul-2009 |
| Rigel to Present at Jefferies Healthcare Conference |
10-Jun-2009 |
| Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers |
1-Jun-2009 |
| Rigel to Present at JMP Securities Research Conference |
13-May-2009 |
| Rigel Announces First Quarter 2009 Financial Results |
5-May-2009 |
| Rigel to Present at Citi's Biotech Day |
27-Mar-2009 |
| Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas |
13-Mar-2009 |
| Rigel to Present at Keystone Symposia Conference |
12-Mar-2009 |
| Rigel to Present at Barclays Capital Healthcare Conference |
6-Mar-2009 |
| Rigel Announces Fourth Quarter and Year End 2008 Financial Results |
24-Feb-2009 |
| Rigel to Present at BIO CEO & Investor Conference |
5-Feb-2009 |
| Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results |
3-Feb-2009 |
| Rigel to Host Conference Call on February 3, 2009 |
2-Feb-2009 |
| Rigel to Present at Keystone Symposia Conference |
23-Jan-2009 |
| Rigel to Participate at the RBC Capital Markets Healthcare Conference |
8-Dec-2008 |
| Phase 2 Results of Rigel's R788 Show Clinical Benefit in Diffuse Large B-Cell Lymphoma and CLL |
7-Dec-2008 |
| Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH |
3-Dec-2008 |
| Rigel to Present at the Piper Jaffray Annual Health Care Conference |
25-Nov-2008 |
| Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism |
11-Nov-2008 |
| Rigel to Present at the 2008 Credit Suisse Healthcare Conference |
11-Nov-2008 |
| Rigel Announces Third Quarter 2008 Financial Results and Clinical Update |
3-Nov-2008 |
| Rigel to Host Update Conference Call |
31-Oct-2008 |
| Rigel to Present at the Oppenheimer 19th Annual Healthcare Conference |
29-Oct-2008 |
| Rigel to Webcast Investor Update on October 27, 2008 |
21-Oct-2008 |
| Rigel to Present at JMP Securities Healthcare Focused Conference |
2-Oct-2008 |
| Rigel to Present at Thomas Weisel Partners Healthcare Conference |
27-Aug-2008 |
| Rigel Announces Second Quarter 2008 Financial Results |
5-Aug-2008 |
| Rigel to Present at Collins Stewart Growth Conference |
3-Jul-2008 |
| Rigel to Present at Jefferies Healthcare Conference |
18-Jun-2008 |
| Rigel Initiates Two Phase 2b Clinical Trials of R788 in Rheumatoid Arthritis |
12-Jun-2008 |
| Rigel to Present at the Needham Biotechnology and Medical Technology Conference |
5-Jun-2008 |
| Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL |
3-Jun-2008 |
| Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma |
2-Jun-2008 |
| Rigel Announces First Quarter 2008 Financial Results |
6-May-2008 |
| Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies |
29-Apr-2008 |
| Rigel's R788 Shows Preclinical Activity in Type 1 Diabetes Model |
8-Apr-2008 |
| Rigel to Present at 8th Annual Fortis Bank Biotechnology Conference |
27-Mar-2008 |
| Rigel Announces Participation in Upcoming Investor and Partnering Conferences |
13-Mar-2008 |
| Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research |
26-Feb-2008 |
| Rigel Announces Fourth Quarter and Year End 2007 Financial Results |
12-Feb-2008 |
| Rigel to Present at BIO CEO & Investor Conference |
6-Feb-2008 |
| Rigel Announces Pricing of Public Offering of Common Stock |
31-Jan-2008 |
| Rigel Announces Offering of 4,000,000 Shares of Common Stock |
24-Jan-2008 |
| Rigel to Present Programs at Four Upcoming Scientific Conferences |
15-Jan-2008 |
| Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders |
9-Jan-2008 |
| Rigel's R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study |
13-Dec-2007 |
| Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer |
6-Dec-2007 |
| Rigel Announces Presentations at the 2007 American Society of Hematology (ASH) Meeting |
5-Dec-2007 |
| Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in ITP |
21-Nov-2007 |
| Merck Serono Exercises Option to Rigel's R763/AS703569 and Aurora Kinase Inhibitors in the Japanese Territory |
14-Nov-2007 |
| Rigel R788 Raises Platelet Counts in Immune Thrombocytopenic Purpura (ITP) Patients in Phase 2 Study |
9-Nov-2007 |
| Rigel Announces Third Quarter 2007 Financial Results |
6-Nov-2007 |
| Rigel Announces Presentations at Upcoming Investor and Partnering Conferences |
30-Oct-2007 |
| Rigel to Present Research Programs at Scientific Conferences |
16-Oct-2007 |
| Rigel to Present at BIO Investor Forum 2007 |
4-Oct-2007 |
| Rigel Announces Presentations at Two Investor Conferences |
28-Aug-2007 |
| Rigel Announces Second Quarter 2007 Financial Results |
7-Aug-2007 |
| Rigel Announces Start of Phase 1 Combination Therapy Study of R763/AS703569 in Advanced Malignancies |
12-Jul-2007 |
| Rigel to Present at Jefferies Healthcare Conference |
21-Jun-2007 |
| Rigel to Present at Needham Biotechnology Conference |
7-Jun-2007 |
| Rigel to Present at JMP Securities Research Conference |
17-May-2007 |
| Rigel Announces First Quarter 2007 Financial Results |
10-May-2007 |
| Rigel Announces Pricing of Public Offering of Common Stock |
2-May-2007 |
| Rigel Announces Offering of 5,000,000 Shares of Common Stock |
30-Apr-2007 |
| Rigel to Present New Research Programs at AACR Meeting |
16-Apr-2007 |
| Rigel Provides Clinical Update of R788 Phase 2 Trials in ITP, Rheumatoid Arthritis and Lymphoma |
11-Apr-2007 |
| Rigel Ubiquitin Ligase Program Identifies Molecules With Anti-HIV Activity |
27-Mar-2007 |
| Rigel Announces Presentation at the Lehman Brothers Global Healthcare Conference |
14-Mar-2007 |
| Rigel Announces Initiation of Phase 1 Study Evaluating R763 in Hematological Malignancies |
13-Feb-2007 |
| Rigel to Present at BIO CEO & Investor Conference 2007 |
7-Feb-2007 |
| Rigel Announces Fourth Quarter and Year End 2006 Financial Results |
6-Feb-2007 |
| Rigel to Present at Upcoming Scientific Conferences |
1-Feb-2007 |
| Rigel Appoints Bradford S. Goodwin to Board of Directors |
25-Jan-2007 |
| Rigel Announces Initiation of Phase II Study Evaluating R788 in Immune Thrombocytopenic Purpura (ITP) |
8-Jan-2007 |
| Rigel to Present at Upcoming Keystone Symposium |
3-Jan-2007 |
| Rigel's R788 Shows Promise for Treating B-Cell Lymphoma and Leukemia in Preclinical Studies |
12-Dec-2006 |
| Rigel Announces Presentation at the Credit Suisse Annual Healthcare Conference |
9-Nov-2006 |
| Rigel Announces Third Quarter 2006 Financial Results |
7-Nov-2006 |
| Rigel Announces Upcoming Presentations at the 2006 American College of Rheumatology (ACR) Annual Meeting |
2-Nov-2006 |
| Rigel Announces Selection of R348, a Novel JAK3 Inhibitor, for Advanced Preclinical Development |
17-Oct-2006 |
| Rigel Announces Presentations at Two Investor Conferences |
12-Oct-2006 |
| Rigel Adds Third Independent Director to Audit Committee |
6-Oct-2006 |
| Rigel Announces Upcoming Presentation at the 14th International Inflammation Research Association (IRA) Conference |
5-Oct-2006 |
| Rigel Announces Initiation of Phase I Study Evaluating R763 in Solid Tumors |
19-Sep-2006 |
| Rigel Announces Initiation of Phase II Study Evaluating R788 in Rheumatoid Arthritis |
6-Sep-2006 |
| Rigel Announces Presentations at Three Investor Conferences |
31-Aug-2006 |
| Rigel Announces Second Quarter 2006 Financial Results |
2-Aug-2006 |
| Rigel Announces Upcoming Presentation at the 2006 Controlled Release Society (CRS) Annual Meeting |
21-Jul-2006 |
| Rigel's Janus Kinase 3 (JAK3) Inhibitors Show Benefit in Organ Transplant Model and Potential Use in Immunosuppression |
19-Jul-2006 |
| Rigel Announces Presentations at the 2006 Targeting Ubiquitin for Drug Discovery and Development Conference |
21-Jun-2006 |
| Rigel and Merck Collaboration Progress Triggers Milestone Payments From Merck in Ligase Partnership |
13-Jun-2006 |
| Rigel Announces Presentations at Two Investor Conferences |
7-Jun-2006 |
| Rigel Names Ryan D. Maynard Vice President of Finance |
6-Jun-2006 |
| Rigel Announces Pfizer Selection of R343, a Syk Kinase Inhibitor, for Advanced Preclinical Development in Allergic Asthma |
17-May-2006 |
| Rigel to Present at Bank of America Annual Healthcare Conference on May 17th, 2006 |
10-May-2006 |
| Rigel to Present at Upcoming Scientific Conferences |
3-May-2006 |
| Rigel Announces First Quarter 2006 Financial Results |
2-May-2006 |
| Rigel Announces Presentations at Two Investor Conferences |
19-Apr-2006 |
| Rigel to Present at the BIO 2006 Annual International Convention |
4-Apr-2006 |
| Rigel Announces Upcoming Presentation on Axl at the 2006 American Association of Cancer Research (AACR) Annual Meeting |
22-Mar-2006 |
| Rigel Granted Key Patents in Immunology, Virology and Oncology |
21-Mar-2006 |
| Rigel to Present at Ninth Annual Lehman Brothers Global Healthcare Conference |
1-Mar-2006 |
| Rigel Announces Completion of R788 Plus Methotrexate Drug Interaction Study in Patients with Rheumatoid Arthritis |
22-Feb-2006 |
| Rigel to Present at BIO CEO & Investor Conference 2006 |
8-Feb-2006 |
| Rigel Announces Fourth Quarter and Year End 2005 Financial Results |
7-Feb-2006 |
| Rigel to Present at Upcoming Scientific Conferences |
1-Feb-2006 |
| Rigel Achieves Milestone with Merck Ligase Collaboration |
30-Jan-2006 |
| Rigel to Receive $5 Million Milestone Payment from Serono for R763 |
26-Jan-2006 |
| Rigel to Present at Upcoming Keystone Symposia |
4-Jan-2006 |
| Rigel Advances Clinical Development Programs for R788 and R763 |
20-Dec-2005 |
| Rigel to Host Investor Briefing on December 15, 2005 |
8-Dec-2005 |
| Rigel's R406/788 Shows Promise for Treating Immune Thrombocytopenia, Hemolytic Anemia and Myeloid Leukemia in Preclinical Studies |
7-Dec-2005 |
| Rigel Announces Disappointing Results from Phase II Study of R112 for the Treatment of Allergic Rhinitis |
1-Dec-2005 |
| Rigel Describes Role of UHRF1, a Ubiquitin Ligase, in Tumor Growth |
28-Nov-2005 |
| Rigel Announces Presentation of Phase I Data on R406/788 at the American College of Rheumatology (ACR) Annual Meeting |
14-Nov-2005 |
| Rigel to Present at Upcoming Investor Conferences |
9-Nov-2005 |
| Rigel Announces Third Quarter 2005 Financial Results |
8-Nov-2005 |
| Rigel Announces Publications Highlighting Two New Screening Mechanisms for Ubiquitin Ligase Inhibitors |
3-Nov-2005 |
| Rigel Announces Presentations at American College of Allergy, Asthma and Immunology (ACAAI) Annual Meeting |
27-Oct-2005 |
| Serono and Rigel Sign Agreement to Develop and Commercialize Aurora Kinase Inhibitors |
25-Oct-2005 |
| Rigel Discovers Novel Angiogenesis and Tumor Formation Roles of Axl Kinase |
18-Oct-2005 |
| Rigel to Present at 2005 BIO Investor Forum |
12-Oct-2005 |
| Rigel Announces Changes to Board of Directors and Appoints Gary A. Lyons |
5-Oct-2005 |
| Rigel to Present at 2005 UBS Life Sciences Conference |
21-Sep-2005 |
| Rigel Announces Presentation at UCSD Frontiers of Clinical Investigation Symposium |
12-Sep-2005 |
| Rigel to Present at Upcoming Investor Conferences |
31-Aug-2005 |
| Rigel Initiates Comparative Phase II Clinical Trial of R112 for the Treatment of Allergies |
9-Aug-2005 |
| Rigel Announces Second Quarter 2005 Financial Results |
3-Aug-2005 |
| Rigel to Present at the Adams Harkness 25th Annual Summer Seminar on Thursday, August 4th |
26-Jul-2005 |
| Rigel to Present at the 2005 FASEB Summer Research Conference |
22-Jul-2005 |
| Rigel Announces Closing of Public Offering of Common Stock |
21-Jul-2005 |
| Rigel Announces Pricing of Common Stock Offering |
15-Jul-2005 |
| Rigel Announces Offering of 3,000,000 Shares of Common Stock |
11-Jul-2005 |
| Rigel's Productivity on Track: HCV and R&D Pipeline Update |
6-Jul-2005 |
| Rigel to Present at Upcoming Investor Conferences |
10-Jun-2005 |
| Rigel to Present at Pacific Growth Equities 2005 Life Sciences Growth Conference |
2-Jun-2005 |
| Rigel to Present at Fourth Annual Needham Biotechnology Conference |
23-May-2005 |
| Rigel to Present at UBS Global Pharmaceuticals Conference |
19-May-2005 |
| Rigel to Present at Banc of America Securities Healthcare Conference |
12-May-2005 |
| Rigel to Present at Bear Stearns 2005 London Healthcare Conference |
6-May-2005 |
| Rigel Receives Two Milestone Payments From Daiichi |
5-May-2005 |
| Rigel Announces First Quarter 2005 Financial Results |
3-May-2005 |
| Rigel to Present at the Deutsche Bank Securities 30th Annual Healthcare Conference on May 2, 2005 |
27-Apr-2005 |
| Rigel to Present at 5th Annual Fortis Bank Biotech Conference on April 27, 2005 |
22-Apr-2005 |
| Rigel Announces Presentations at the 96th Annual Meeting of the American Association for Cancer Research (AACR) |
15-Apr-2005 |
| Rigel to Present at White Mountain Capital Third Annual Biotechnology Conference on April 19, 2005 |
14-Apr-2005 |
| Efficacy and Safety Clinical Data for Rigel's R112 Phase II Study Published in Journal of Allergy and Clinical Immunology |
6-Apr-2005 |
| Rigel Completes Phase I Clinical Trial of R406 in Rheumatoid Arthritis |
31-Mar-2005 |
| Rigel to Present at the Lehman Brothers Eighth Annual Global Healthcare Conference on March 31, 2005 |
24-Mar-2005 |
| Rigel Presents Clinical Data at the American Academy of Allergy, Asthma and Immunology |
17-Mar-2005 |
| Rigel to Present at Wells Fargo Securities 2005 Healthcare Conference |
24-Feb-2005 |
| Rigel to Present at BIO CEO & Investor Conference on February 24, 2005 |
17-Feb-2005 |
| Rigel Announces Fourth Quarter and Year End 2004 Financial Results |
8-Feb-2005 |
| Rigel Pharmaceuticals Announces Changes to Board of Directors and Appoints Peter S. Ringrose, Ph.D. |
3-Feb-2005 |
| Rigel and Pfizer Sign Collaborative Research and License Agreement for the Treatment of Allergic Asthma and Other Respiratory Diseases |
20-Jan-2005 |
| Rigel to Present at the 23rd Annual JPMorgan Healthcare Conference on January 13, 2005 |
7-Jan-2005 |
| Rigel Initiates Clinical Trial in Rheumatoid Arthritis |
21-Dec-2004 |
| Rigel to Host Investor Briefing on December 1, 2004 |
29-Nov-2004 |
| Poor Bioavailability Results in Insignificant Clinical Effects for Rigel R803 in Phase I/II HCV Trial |
22-Nov-2004 |
| Merck and Rigel Pharmaceuticals Sign Ligase Partnership With a Primary Focus on Cancer |
15-Nov-2004 |
| Rigel to Present at the CSFB Annual Healthcare Conference on November 17, 2004 |
12-Nov-2004 |
| Rigel Announces Third Quarter 2004 Financial Results |
5-Nov-2004 |
| Rigel Presents Preclinical Data at the 68th Annual Scientific Meeting of the American College of Rheumatology |
20-Oct-2004 |
| Rigel to Present at the UBS Global Life Sciences Conference on September 27, 2004 |
21-Sep-2004 |
| Rigel to Present at the Thomas Weisel Partners Healthcare Tailwinds Conference on September 8, 2004 |
2-Sep-2004 |
| Rigel Announces Second Quarter 2004 Financial Results |
3-Aug-2004 |
| Rigel's R112 Demonstrates Robust Effect in Reducing Symptoms of Allergic Rhinitis in Large Phase II Clinical Trial |
2-Aug-2004 |
| Rigel to Present at the Adams Harkness 2004 Summer Seminar on August 4, 2004 |
28-Jul-2004 |
| Rigel Reports Significant Progress in Aurora Kinase Program for the Treatment of Cancer |
22-Jul-2004 |
| Rigel Appoints Raul Rodriguez as Executive Vice President and Chief Operating Officer |
16-Jun-2004 |
| Rigel to Present at Two Investor Conferences |
10-Jun-2004 |
| Rigel Granted Key Patents in Ubiquitin Ligase Field |
9-Jun-2004 |
| Rigel to Present at the BIO 2004 International Convention June 7, 2004 |
4-Jun-2004 |
| Rigel Initiates Phase I/II Trial of R803 for the Treatment of Hepatitis C Virus |
24-May-2004 |
| Rigel to Present at the UBS 2004 Global Specialty Pharmaceuticals Conference on May 24, 2004 |
20-May-2004 |
| Rigel to Present at The Rodman & Renshaw Techvest Global Healhcare Conference On May 13, 2004 |
6-May-2004 |
| Rigel Announces First Quarter 2004 Financial Results |
4-May-2004 |
| Rigel to Present at the 4th Annual Fortis Bank Biotech Conference |
29-Apr-2004 |
| Rigel Initiates Phase II Clinical Trial of R112 for Allergic Rhinitis |
20-Apr-2004 |
| Rigel to Present at the 2nd Annual White Mountain Capital Biotechnology Conference |
15-Apr-2004 |
| Rigel Announces Underwriters' Exercise of Option to Purchase Additional Shares |
25-Mar-2004 |
| Rigel Presents Positive Results of R112 Clinical Trial for the Treatment of Allergic Rhinitis |
18-Mar-2004 |
| Rigel to Present at the 6th Annual BIO CEO and Investor Conference |
24-Feb-2004 |
| Rigel Announces Pricing of Common Stock Offering |
20-Feb-2004 |
| Rigel Announces Offering of 3,165,000 Shares of Common Stock |
20-Feb-2004 |
| Rigel Announces Offering of 3,165,000 Shares of Common Stock |
6-Feb-2004 |
| Rigel Announces Fourth Quarter and Year End 2003 Financial Results |
3-Feb-2004 |
| Rigel Selects R406 as Lead Drug Candidate for Rheumatoid Arthritis |
28-Jan-2004 |
| Rigel's R803 for HCV Achieves Favorable Safety Profile |
26-Jan-2004 |
| Rigel Pharmaceuticals Appoints Hollings C. Renton to Board of Directors |
21-Jan-2004 |
| Rigel Announces Issuance of HCV and Inflammation Patents |
6-Jan-2004 |
 |
